GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

Bicycle Therapeutics BCYC · USD

Health Care · US listing · 🇺🇸 United States

Compare

3.77

+4.43%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Bicycle Therapeutics

From its filings with the US Securities and Exchange Commission

SEC filings

Bicycle Therapeutics is based in Cambridge, United Kingdom and is incorporated in United Kingdom. Its shares trade on Nasdaq under the ticker BCYC. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $72.6m and a net loss of $219.0m. At that date it held total assets of $717.6m and shareholders' equity of $610.0m.

In its own words

We have a novel and proprietary phage display screening platform which we use to identify Bicycle molecules in an efficient manner. The platform initially displays linear peptides on the surface of engineered bacteriophages, or phages, before “on-phage” cyclization with a range of small molecule scaffolds which can confer differentiated physicochemical and structural properties. Our platform encodes quintillions of potential Bicycle molecules which can be screened to identify molecules for optimization to potential product candidates. We have used this powerful screening technology to identify our current portfolio of candidates in oncology and intend to use it in conjunction with our collaborators to seek to develop additional future candidates across a range of other disease areas.

Our internal programs are focused on oncology indications with high unmet medical need. Our product candidate, nuzefatide pevedotin, formerly BT5528, is a Bicycle Drug Conjugate, or a BDC® molecule, whereby the Bicycle molecule is chemically attached to a toxin that, when administered, is cleaved from the Bicycle molecule and kills the tumor cells.

Quoted from its 10-K, filed 17 Mar 2026. Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
23 May 2019
Employees
288
Head office
BLOCKS A & B, PORTWAY BUILDING, CAMBRIDGE, X0, CB21 6GS
Incorporated in
X0
Classification
Pharmaceutical Preparations
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Felix BakerNon-Executive Independent Chairman of the Board$658,317
  • Dr. Kevin LeeChief Executive Officer, Executive Director, since 2015$4.9m
  • Mr. Travis ThompsonChief Financial Officer
  • Mr. Alistair MilnesChief Operating Officer$2.6m
  • Dr. Michael SkynnerChief Technology Officer$3.1m
  • Mr. Michael HannayChief Product and Supply Chain Officer$2.4m
  • Mr. Eric WestinChief Medical Officer
  • Ms. Janice BourqueNon-Executive Independent Director$343,436
  • Dr. Jose Gutierrez-RamosNon-Executive Independent Director$342,175
  • Dr. Roger DanseyIndependent Director
  • Mr. Herve HoppenotIndependent Director
  • Dr. Charles SwantonIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.